ATE90570T1 - Verbesserte formulierungen mit kontrollierter abgabe. - Google Patents

Verbesserte formulierungen mit kontrollierter abgabe.

Info

Publication number
ATE90570T1
ATE90570T1 AT89101428T AT89101428T ATE90570T1 AT E90570 T1 ATE90570 T1 AT E90570T1 AT 89101428 T AT89101428 T AT 89101428T AT 89101428 T AT89101428 T AT 89101428T AT E90570 T1 ATE90570 T1 AT E90570T1
Authority
AT
Austria
Prior art keywords
controlled delivery
delivery formulations
formulation
improved controlled
active ingredient
Prior art date
Application number
AT89101428T
Other languages
English (en)
Inventor
Keiji Fujioka
Shigeji Sato
Nobuhiko Tamura
Yoshihiro Takada
Yoshio Sasaki
Miho Maeda
Original Assignee
Sumitomo Pharma
Koken Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma, Koken Kk filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE90570T1 publication Critical patent/ATE90570T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89101428T 1988-01-29 1989-01-27 Verbesserte formulierungen mit kontrollierter abgabe. ATE90570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2045988 1988-01-29
EP89101428A EP0326151B1 (de) 1988-01-29 1989-01-27 Verbesserte Formulierungen mit kontrollierter Abgabe

Publications (1)

Publication Number Publication Date
ATE90570T1 true ATE90570T1 (de) 1993-07-15

Family

ID=12027662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89101428T ATE90570T1 (de) 1988-01-29 1989-01-27 Verbesserte formulierungen mit kontrollierter abgabe.

Country Status (6)

Country Link
US (1) US5236704A (de)
EP (1) EP0326151B1 (de)
AT (1) ATE90570T1 (de)
CA (1) CA1338839C (de)
DE (1) DE68907066T2 (de)
ES (1) ES2058351T3 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
GR1002610B (el) * 1991-01-02 1997-02-20 Johnson & Johnson Consumer Products Inc. Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
EP0578823B1 (de) * 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
WO1995002411A1 (en) * 1993-07-16 1995-01-26 Mallinckrodt Veterinary Limited Stabilised polypeptide growth factor formulation at low ph
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
EP1217101B8 (de) 1994-04-29 2006-02-01 Boston Scientific Scimed, Inc. Stent mit Kollagen
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
DE19739031A1 (de) * 1997-09-05 1999-03-11 Suwelack Nachf Dr Otto Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
WO1999061063A1 (fr) * 1998-05-22 1999-12-02 Sumitomo Pharmaceuticals Company, Limited Preparations geniques stables
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
WO2003066083A1 (fr) * 2002-02-04 2003-08-14 Sumitomo Pharmaceuticals Company, Limited Preparations pour le traitement de fracture osseuse de deperdition osseuse ou d'augmentation la densite osseuse
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7205281B2 (en) 2003-10-03 2007-04-17 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
US7718616B2 (en) * 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠***的递送
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8905913B2 (en) 2009-04-23 2014-12-09 Jbs United Animal Health Ii Llc Method and composition for synchronizing time of insemination
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
RU2015125549A (ru) 2012-11-28 2017-01-11 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ для синхронизации времени осеменения молодых свиней
EP3718557A3 (de) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294241A (en) * 1977-06-09 1981-10-13 Teruo Miyata Collagen skin dressing
US4164559A (en) * 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
DE3250023T (de) * 1981-01-14 1990-03-29
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
JPS597684A (ja) * 1982-07-05 1984-01-14 株式会社日立製作所 エスカレ−タ−
JPS5919925A (ja) * 1982-07-27 1984-02-01 Stanley Electric Co Ltd ２層式液晶セルの製造方法
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
EP0138216B1 (de) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3409372A1 (de) * 1984-03-14 1985-09-19 Dr. Ruhland Nachf. GmbH, 8425 Neustadt Material zum vitalisieren von implantatoberflaechen
ES2054613T3 (es) * 1985-12-27 1994-08-16 Sumitomo Pharma Un metodo para preparar una formulacion de liberacion mantenida.
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5057317A (en) * 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法

Also Published As

Publication number Publication date
DE68907066D1 (de) 1993-07-22
US5236704A (en) 1993-08-17
ES2058351T3 (es) 1994-11-01
EP0326151A3 (de) 1991-03-13
EP0326151B1 (de) 1993-06-16
EP0326151A2 (de) 1989-08-02
DE68907066T2 (de) 1993-12-16
CA1338839C (en) 1997-01-14

Similar Documents

Publication Publication Date Title
DE68907066D1 (de) Verbesserte formulierungen mit kontrollierter abgabe.
NO921002L (no) Nye estere av tienylkarboksylsyrer og aminoalkoholer, deres kvartaeriseringsprodukter, og fremstilling og anvendelseav forbindelsene
HUT65415A (en) Fluoralkenyl compounds, their use as pest repellents and pesticides, pesticides containing the compounds as active ingredients, and process for producing the compounds
AU7340387A (en) Controlled release bases for pharmaceuticals
GT199600098A (es) Formulaciones de quinolona inyectables.
YU221889A (en) Process for producing new pharmaceutical mixture
ATE137795T1 (de) Verbessertes träger- und freisetzungssystem von riechstoffen für die wäschebehandlung
ES2070109T3 (es) Sales diaminicas de acido clavulanico.
MX10146A (es) Procedimiento para la produccion de preparados medicinales que contienen y liberan sustancias activas y producto obtenido.
ES2115916T3 (es) Procedimiento para la preparacion de compuestos de triazolona.
ES2081417T3 (es) Procedimiento para la preparacion de acido 5-(2,4-difluorofenil)-salicilico.
NO870950L (no) FremgangsmŸte for fremstilling av et stabilt injiserbart farmasŸytisk preparat.
ES2099728T3 (es) Procedimiento para la preparacion de acidos 2,3-piridin- y quinolindicarboxilicos sustituidos y no sustituidos.
ES2130392T3 (es) Procedimiento para la preparacion de acido clavulanico.
ES2055379T3 (es) Utilizacion de un desodorante para alimentos destinados a animales a base de ester de acido undecilenico, y alimentos para animales que contienen dicho ester.
NO168470C (no) Fremgangsmaate for fremstilling av 5-hydroksydiprafenon ogsyreaddisjonssalter derav.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee